20.59
Dianthus Therapeutics Inc stock is traded at $20.59, with a volume of 190.85K.
It is down -0.72% in the last 24 hours and down -11.78% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$20.74
Open:
$20.7
24h Volume:
190.85K
Relative Volume:
0.72
Market Cap:
$661.46M
Revenue:
$4.12M
Net Income/Loss:
$-56.68M
P/E Ratio:
-3.7147
EPS:
-5.5429
Net Cash Flow:
$-51.44M
1W Performance:
-5.98%
1M Performance:
-11.78%
6M Performance:
-26.73%
1Y Performance:
-22.13%
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
DNTH
Dianthus Therapeutics Inc
|
20.59 | 661.46M | 4.12M | -56.68M | -51.44M | -5.5429 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-20-24 | Initiated | TD Cowen | Buy |
Oct-03-24 | Initiated | Oppenheimer | Outperform |
Jul-26-24 | Initiated | Robert W. Baird | Outperform |
Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
May-16-24 | Initiated | H.C. Wainwright | Buy |
Feb-15-24 | Initiated | Stifel | Buy |
Dec-26-23 | Initiated | Jefferies | Buy |
Nov-22-23 | Initiated | Wedbush | Outperform |
Oct-30-23 | Initiated | Guggenheim | Buy |
Sep-28-23 | Initiated | Raymond James | Outperform |
Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
Aug-20-21 | Resumed | Goldman | Neutral |
Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-22-21 | Reiterated | B. Riley Securities | Buy |
Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
Jun-15-21 | Initiated | BTIG Research | Buy |
May-18-21 | Initiated | B. Riley Securities | Buy |
Jan-07-21 | Initiated | Mizuho | Buy |
Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
FY2025 Earnings Forecast for DNTH Issued By Lifesci Capital - MarketBeat
Wedbush Equities Analysts Reduce Earnings Estimates for DNTH - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.8%Here's Why - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
FY2025 EPS Estimates for DNTH Raised by Cantor Fitzgerald - Defense World
Q1 EPS Estimate for Dianthus Therapeutics Lifted by Analyst - MarketBeat
HC Wainwright Issues Optimistic Outlook for DNTH Earnings - Defense World
Dianthus Therapeutics' (DNTH) Outperform Rating Reiterated at Wedbush - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap DownWhat's Next? - MarketBeat
Dianthus Therapeutics (DNTH) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 5.5%Here's Why - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Issues Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Research Analysts Set Expectations for DNTH Q1 Earnings - Defense World
HC Wainwright Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Guggenheim Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Wedbush Reaffirms “Outperform” Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics' (DNTH) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat
We're Not Very Worried About Dianthus Therapeutics' (NASDAQ:DNTH) Cash Burn Rate - Yahoo Finance
Dianthus Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Dianthus Therapeutics (DNTH) to Release Quarterly Earnings on Thursday - Defense World
Dianthus Therapeutics Reports 2024 Financial Results and Clinical Progress - TipRanks
Stifel maintains Buy rating on Dianthus Therapeutics stock By Investing.com - Investing.com Canada
Dianthus Therapeutics shares fall as Q4 results miss expectations By Investing.com - Investing.com South Africa
Dianthus Therapeutics shares fall as Q4 results miss expectations - Investing.com India
Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress - TipRanks
Dianthus Therapeutics: Strong Financials and Promising Clinical Trials Justify Buy Rating - TipRanks
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Buy” by Brokerages - Defense World
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates - Nasdaq
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results - The Manila Times
Dianthus Therapeutics, Inc. /DE/ SEC 10-K Report - TradingView
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 - Bluefield Daily Telegraph
Dianthus Therapeutics: Promising Growth Potential with Innovative DNTH103 and Strong Financial Position - TipRanks
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 8.2%Still a Buy? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year LowShould You Sell? - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Boosted by Rhumbline Advisers - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.3%Should You Sell? - MarketBeat
John King named commercial head at Dianthus - BioCentury
Dianthus Therapeutics appoints John King as CCO By Investing.com - Investing.com Canada
Dianthus Therapeutics Appoints Sujay Kango to Board - TipRanks
Dianthus Therapeutics announces board changes - Investing.com India
Dianthus Therapeutics appoints John King as CCO - Investing.com India
Dianthus Therapeutics announces board changes By Investing.com - Investing.com UK
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):